期刊文献+

伊贝沙坦与复方丹参联合应用对早期糖尿病肾病患者肾功能及血液流变学的影响 被引量:3

Effects of irbesartan combined with dan-shen root on the kidney function and the hemorheology in patients with early diabetic nephropathy
暂未订购
导出
摘要 目的伊贝沙坦与复方丹参联合应用对早期糖尿病肾病患者肾功能及血液流变学的影响及安全性。方法 80例早期糖尿病肾病患者采用随机数字表法分为观察组和对照组各40例,均给予糖尿病常规治疗,在此基础上,对照组加用贝那普利,观察组加用伊贝沙坦及复方丹参,治疗3个月后评价对肾功能及血液流变学的影响。结果①两组治疗后空腹血糖(FPG)、餐后2 h血糖(P2 hPG)、糖化血红蛋白(HbA1c)水平均无明显变化,治疗前后差异均无统计学意义(P>0.05)。②两组血尿素氮(BUN)、24 h尿蛋白量、收缩压、舒张压较治疗前均明显下降(P<0.05),肌酐清除率(Ccr)明显上升(P<0.05),但观察组BUN、24 h尿蛋白量和Ccr改善更明显(P<0.05)。③治疗后观察组血液流变学各项指标明显改善(P<0.05),而对照组与治疗前比较变化不大(P>0.05)。④两组均未发生严重不良反应。结论伊贝沙坦与复方丹参联合应用治疗早期糖尿病肾病患者,可以有效降低血压,改善肾功能及血液流变学,安全性高,值得临床推广应用。 Objective To investigate the effects of irbesartan combined with dan-shen root on the kidney function and the hemorheology in patients with early diabetic nephropathy. Methods Eighty patients with early diabetic nephropathy were randomly divid- ed into observation group and control group ,40 patients each group. All the patients were treated with conventional therapy for diabe- tes. The control group was additionally treated with benazepril while the observation group additionally treated with irbesartan and dan- shen root. The effects were evaluated in 3 months after treatment. Results:①No significant changes in fasting plasma glucose( FPG), postprandial 2 h plasma glucose( P2 hPG)and glyeosylated hemoglobin(HbAle) were found neither in the control or the observe group before and after the treatment. ②In the two groups, blood urea nitrogen (BUN) ,24 h urine protein volume, systolic pressure and dias- tolic pressure were significantly decreased while creatinine clearance rate(Ccr) was significantly increased after 3 months of the treatment when compared to treatment before( all P 〈 0.05 ). However,the improvement of 24 h urine protein volume and Ccr in the obser- vation group were more significantly than that in the control group( P 〈 0.05 ). ③The hemorheological indexes of the observation group were significantly improved( P 〈 0. 05 )while no significant changes was found in the control group after 3 months of the treatment when compared to treatment before. (~No severe adverse reaction occurred neither in the control or the observe group. Conclusions The treatment with irbesartan combined with dan-shen root for early diabetic nephropathy can effectively decrease blood pressure, improve kidney function and hemorheology, and is highly safe. Therefore, the treatment is worthy of clinical application.
作者 贾学元
出处 《实用医院临床杂志》 2013年第4期152-154,共3页 Practical Journal of Clinical Medicine
关键词 伊贝沙坦 复方丹参 贝那普利 糖尿病肾病 Irbesartan Dan-shen root Benazepril Diabetic nephropathy
  • 相关文献

参考文献8

二级参考文献22

  • 1蒲琳,陆志明,林肯,吴桐.中西医结合治疗糖尿病肾病36例体会[J].实用医院临床杂志,2010,7(4):128-129. 被引量:4
  • 2梁晓春,郭赛珊,王香定,田国庆,韩少梅.糖尿病合并冠心病与脂质过氧化关系研究及中医辨证分型特点[J].中国中西医结合杂志,1996,16(1):29-31. 被引量:20
  • 3邹大进,陈月.糖尿病微血管并发症的发病机制及治疗[J].中华糖尿病杂志(1006-6187),2005,13(5):393-395. 被引量:41
  • 4Gross G,Azevedo MJ,Silveiro SP,et al.Diabetic nephropathy:diagno prevention,and treatment[J].Diabetes Care,2005,28(1):164-176.
  • 5董砚虎 钱荣立.糖尿病及其并发症的治疗.山东医药,2006,16(4):286-287.
  • 6陈灏珠.一起由酸败油脂引起的食物中毒[J].实用内科学[M]第11版[M].北京:人民卫生出版社,2001.917-919.
  • 7陈灏珠.实用内科学[M].北京:人民卫生出版社,2005.1850.
  • 8吕仁和 主编.糖尿病及其并发症中西医诊治学[M].北京:人民卫生出版社,1998.329.
  • 9Mogensen CE ,Keane Bennett. PH, et al. Prevention of diabetic renal disease with special reference to microal baminuria Lancet, 1995,346(8982):1080-1084
  • 10Hollsnberg NK ACE inhibior, AT1 receptor blockers, and kidnsy, Niphrol Kial Transp, 1997,12:381

共引文献32

同被引文献30

  • 1金荣泉,唐晓清.复方丹参制剂的临床应用及不良反应研究概况[J].中国现代应用药学,2005,22(z3):838-839. 被引量:3
  • 2张媛英,翟静,孙凌云,蒋汉明,张凤珍,顾洪雁.何首乌提取物对大鼠脑缺血再灌注损伤的保护作用[J].中国临床康复,2005,9(33):86-87. 被引量:12
  • 3姚新生.天然药物化学[M].3版.北京:人民卫生出版社,2000.
  • 4Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12) :1090-1101.
  • 5Vejakama P, Thakkinstian A, Lertrattananon D, et al. Re- no-protective effects of renin-an giotensin system blockade in type 2 diabetic patients:a systematic review and net- work meta-analysis[J]. Diabetologia, 2012, 55 ( 3 ) : 566- 578.
  • 6Lemley KV. When to initiate ACEI/ARB therapy in pa- tients with type 1 and 2 diabetes[J]. Pediatr Nephrol, 2010,25 (10): 2021-2084.
  • 7Kim SI, Han DC, Lee HB. Lovastatin inhibits transfor- ming growth factor-betal expression in diabetic rat glomemli and cultured rat mesangial cells[J]. J Am Soc Nephrol, 2000,11 ( 1 ) : 80-87.
  • 8Ha H,Kim KH.Pathogenesis of diabetic nephropathy:the role of oxidative stress and protein kinase C[J].Diabetes Res Clin Pract,1999,45(2/3):147.
  • 9Alberti KG,Zimmet PZ.Definition,diagnosis and classification of diabetes mellitus and its complications:report of a WHO consultation.Part I:diagnosis and classification of diabetes mellitus.Provisional report of WHD consultation[J].Diabet Med,1998,15(7):539.
  • 10Remuzzi G,Schieppati A,Ruggenenti P.Clinical practice.Nephropathy in patients with type 2 diabetes[J].NEngl J Med,2002,346(15):1 145.

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部